Banff Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2003
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibody-Based Therapeutics for Cancer (B4)
Organizer(s) Louis M. Weiner and Paul Carter
February 4—9, 2003
Banff Centre • Banff, Alberta Canada
Abstract Deadline: Oct 3, 2002
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 4, 2002
Sponsored by Amgen Inc.
Summary of Meeting:
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected unconjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphomas. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new targets, including structurally-defined (e.g., through proteomic or genomic screening) and functionally-defined approaches. New approaches are needed to harness the ability of antibodies to initiate and sustain innate and adaptive immune responses. For immunoconjugate strategies to consistently succeed without undue host toxicity, new strategies must be developed to dissociate the process of antibody distribution from the effects of antibody-directed tumor targeting. This meeting will address these challenges in distinct sessions devoted to antibody structure and function, immunoconjugates, antibodies as tools for target discovery, antibodies as signaling agents and immune effectors, and in a session that highlights clinical advances in the field. Leaders in each of these areas will present their work and discussion periods will be used to highlight areas felt to have particular promise.
View Scholarships/Awards
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected unconjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphomas. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new targets, including structurally-defined (e.g., through proteomic or genomic screening) and functionally-defined approaches. New approaches are needed to harness the ability of antibodies to initiate and sustain innate and adaptive immune responses. For immunoconjugate strategies to consistently succeed without undue host toxicity, new strategies must be developed to dissociate the process of antibody distribution from the effects of antibody-directed tumor targeting. This meeting will address these challenges in distinct sessions devoted to antibody structure and function, immunoconjugates, antibodies as tools for target discovery, antibodies as signaling agents and immune effectors, and in a session that highlights clinical advances in the field. Leaders in each of these areas will present their work and discussion periods will be used to highlight areas felt to have particular promise.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, FEBRUARY 4
WEDNESDAY, FEBRUARY 5
THURSDAY, FEBRUARY 6
FRIDAY, FEBRUARY 7
SATURDAY, FEBRUARY 8
SUNDAY, FEBRUARY 9
Conference Program Print | View meeting in 12 hr (am/pm) time
TUESDAY, FEBRUARY 4
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.
Sir Greg Winter,
Trinity College Cambridge, UK
Evolution and the Antibody Binding Site
Evolution and the Antibody Binding Site
08:00—11:00
Antibody Structure and Function I
Meeting has ended...abstracts no longer viewable online.
*
Paul Carter,
Genentech, Inc., USA
Leonard Presta,
DNAX Research Institute, USA
Engineering Therapeutic Antibodies for Improved Function
Engineering Therapeutic Antibodies for Improved Function
Raphael Clynes,
Xencor, Inc., USA
Fc Receptors: Contributions to Antibody-Mediated Tumor Immunity
Fc Receptors: Contributions to Antibody-Mediated Tumor Immunity
Peter J. Hudson,
Aviper, Pty., Ltd., Australia
Design and Characterization of Multivalent Antibody Molecules
Design and Characterization of Multivalent Antibody Molecules
Andreas G. Plückthun,
University of Zürich, Switzerland
Biophysical Properties of Antibody Fragments: Importance for Applications
Biophysical Properties of Antibody Fragments: Importance for Applications
17:00—17:35
Antibody Structure and Function II
Meeting has ended...abstracts no longer viewable online.
Ian M. Tomlinson,
GlaxoSmithKline, UK
Fully Human Domain Antibodies as Therapeutics
Fully Human Domain Antibodies as Therapeutics
17:35—19:00
Antibodies as Tools for Target Discovery
Meeting has ended...abstracts no longer viewable online.
*
James D. Marks,
University of California, San Francisco, USA
Tumor Cell Binding and Internalizing Antibodies from Phage Libraries
Tumor Cell Binding and Internalizing Antibodies from Phage Libraries
Brian B. Haab,
Van Andel Institute, USA
Analysis of Blood Proteins from Prostate and Pancreatic Cancer Patients using Antibody Microarrays
Analysis of Blood Proteins from Prostate and Pancreatic Cancer Patients using Antibody Microarrays
08:00—11:00
Immunoconjugates I
Meeting has ended...abstracts no longer viewable online.
Peter D. Senter,
Seattle Genetics Inc., USA
Highly Potent Immunoconjugates for the Treatment of Cancer
Highly Potent Immunoconjugates for the Treatment of Cancer
Ralph A. Reisfeld,
The Scripps Research Institute, USA
Immunoctyokines for Cancer Immunotherapy
Immunoctyokines for Cancer Immunotherapy
*
Richard H.J. Begent,
University College London, UK
Antibody-Directed Enzyme Prodrug Therapy: Preclinical and Clinical Development with an Engineered Fusion Protein
Antibody-Directed Enzyme Prodrug Therapy: Preclinical and Clinical Development with an Engineered Fusion Protein
Carlos F. Barbas III,
The Scripps Research Institute, USA
Chemical Approaches to Cancer Immunotherapy
Chemical Approaches to Cancer Immunotherapy
17:00—19:00
Immunoconjugates II
Meeting has ended...abstracts no longer viewable online.
*
Ellen S. Vitetta,
University of Texas Southwestern Medical Center, USA
Engineering Toxins to Avoid VLS
Engineering Toxins to Avoid VLS
Richard J. Youle,
NINDS, National Institutes of Health, USA
Targeting of Bcl-2 Family Proteins to Regulate Apoptosis
Targeting of Bcl-2 Family Proteins to Regulate Apoptosis
Martin J. Glennie,
University of Southampton, UK
Selecting CD20 Antibodies for Optimal Effector Function
Selecting CD20 Antibodies for Optimal Effector Function
08:00—11:00
Advances in Antibody Engineering
Meeting has ended...abstracts no longer viewable online.
*
Hennie R. Hoogenboom,
Ablynx, Belgium
Exploiting Phage Display Libraries for Cancer Diagnosis and Therapy
Exploiting Phage Display Libraries for Cancer Diagnosis and Therapy
Kathrin Tissot,
MorphoSys AG, Germany
Intracellularly Stable Antibodies for Therapy and Target Validation
Intracellularly Stable Antibodies for Therapy and Target Validation
Terence H. Rabbitts,
MRC Laboratory of Molecular Biology, UK
Intracellular Antibody Capture (IAC): The Second Generation
Intracellular Antibody Capture (IAC): The Second Generation
Quan Karen Zhu,
Dana Farber Cancer Institute, USA
Intrabodies as Tools to Mediate Protein Function
Intrabodies as Tools to Mediate Protein Function
17:00—19:00
Applications of Antibody Engineering
Meeting has ended...abstracts no longer viewable online.
Gregory P. Adams,
Sesen Bio, USA
Targeting the Epidermal Growth Factor Receptor Family with Heterodimeric Single-Chain FV Molecules
Targeting the Epidermal Growth Factor Receptor Family with Heterodimeric Single-Chain FV Molecules
*
Anna M. Wu,
University of California, Los Angeles, USA
Engineering Antibody Fragments for Targeting and Pharmacokinetic Properties
Engineering Antibody Fragments for Targeting and Pharmacokinetic Properties
20:00—21:00
Workshop 1
*
Anna M. Wu,
University of California, Los Angeles, USA
Bryan Edwards,
, UK
Isolation of Agonistic Human Monoclonal Antibodies to TRAIL-R2 that Display Potent in vitro and in vivo Anti-Tumour Activities
Isolation of Agonistic Human Monoclonal Antibodies to TRAIL-R2 that Display Potent in vitro and in vivo Anti-Tumour Activities
Mark S. Dennis,
Denali Therapeutics, USA
Improved Tumor Targeting Using an Fab with a Prolonged Half-Life
Improved Tumor Targeting Using an Fab with a Prolonged Half-Life
Marielle A. Otten,
UMC-Utrecht, Netherlands
Immunoglobulin A Receptor (FcaRI) as Target for Antibody Immunotherapy
Immunoglobulin A Receptor (FcaRI) as Target for Antibody Immunotherapy
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
Cell Line Engineering for Production of Therapeutic Antibody Glycoforms with Increased Biological Activity
Cell Line Engineering for Production of Therapeutic Antibody Glycoforms with Increased Biological Activity
Robert M. Sharkey,
Garden State Cancer Center, USA
Development of a Bispecific Antibody (bsMAb) Pretargeting System for the Treatment of CEA-Expressing Tumors: Clinical Studies to Define the Optimal Conditions for Delivering an 131I-Peptide
Development of a Bispecific Antibody (bsMAb) Pretargeting System for the Treatment of CEA-Expressing Tumors: Clinical Studies to Define the Optimal Conditions for Delivering an 131I-Peptide
08:00—10:30
Antibodies as Effector Molecules
Meeting has ended...abstracts no longer viewable online.
Mark X. Sliwkowski,
Genentech, Inc., USA
Therapeutic Approaches to Targeting ErbB2/HER2 in Solid Tumors
Therapeutic Approaches to Targeting ErbB2/HER2 in Solid Tumors
*
Louis M. Weiner,
Georgetown University Medical Center, USA
Selective Manipulation of Immune Response Using Antibody-Based Fusion Proteins
Selective Manipulation of Immune Response Using Antibody-Based Fusion Proteins
Dario Neri,
ETH Zürich, Switzerland
Antibody-Promoted Tumor Blood Vessels Thrombosis
Antibody-Promoted Tumor Blood Vessels Thrombosis
17:00—19:00
Clinical Updates
Meeting has ended...abstracts no longer viewable online.
Mark D. Pegram,
Stanford Cancer Institute, USA
Antibodies Targeting HER2
Antibodies Targeting HER2
*
George J. Weiner,
University of Iowa, USA
Monoclonal Antibody Therapy of B Cell Lymphoma: What's Next?
Monoclonal Antibody Therapy of B Cell Lymphoma: What's Next?
Gisela Schwab,
Exelixis, Inc., USA
ABX-EGF, a Fully Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb)
ABX-EGF, a Fully Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb)
David A. Reardon,
Duke University Medical Center, USA
Short Talk: Radiolabeled Anti-Tenascin Monoclonal Antibody 81C6 Administered into Surgical Resection Cavities in the Treatment of Patients with Malignant Brain Tumors
Short Talk: Radiolabeled Anti-Tenascin Monoclonal Antibody 81C6 Administered into Surgical Resection Cavities in the Treatment of Patients with Malignant Brain Tumors
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
